New Video: Lung NETs and DIPNECH
Luncheon with the Experts Continues
Daniel M. Halperin, MD, will be the featured guest for Luncheon with the Experts on Thursday, February 25, 2021 from 12 noon to 1 pm, Eastern Time. A medical oncologist and clinical investigator, Dr. Halperin focuses on the development of novel treatments for patients with neuroendocrine tumors (NETs), in addition to providing clinical care to patients with NETs and other gastrointestinal cancers. He leads clinical trials of new drugs for patients with NETs at MD Anderson Cancer Center in Texas, and works with a team of laboratory and population scientists to understand more fully the molecular underpinnings and clinical manifestations of neuroendocrine tumors. READ MORE
NANETS Issues Position Statement on COVID-19 Vaccination for NET and NEC Patients
A growing body of evidence suggests that patients with cancer have an increased risk of severe COVID-19 infection and related complications. NANETS, the North American Neuroendocrine Tumor Society, has issued a Position Statement regarding the plan for COVID-19 vaccination for patients with neuroendocrine neoplasms (NENs), including well differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). NEN survivors and patients with NENs on observation or undergoing cancer treatment should be offered COVID-19 vaccination as long as any components of the vaccine are not contraindicated. READ MORE
Facebook Live Program on Carcinoid Syndrome: Managing Breakthrough Symptoms
Are you newly diagnosed with carcinoid syndrome or have been living with the syndrome for many years?
The Carcinoid Cancer Foundation presented a Facebook Live program on Carcinoid Syndrome on December 14th featuring neuroendocrine tumor (NET) expert Lowell Anthony, MD, FACP, Chief of the Division of Medical Oncology at the UK Markey Cancer Center in Lexington, Kentucky, and NET patient Melanie Bean. The live program offered viewers the opportunity to ask questions of Dr. Anthony and Ms. Bean and covered living with carcinoid syndrome and how to manage breakthrough symptoms.
If you were not able to join us for the live program, it is now available for viewing on CCF’s Facebook page here, https://www.facebook.com/271774129226/videos/2949405928614542. For anyone who is not on Facebook, it is available for viewing on CCF’s YouTube channel here, https://youtu.be/xSLCXjYEb1s.
This special program is made possible with sponsorship by Sun Pharmaceuticals Industries Inc.
Detectnet Transitional Pass-Through Status Granted by Centers for Medicare and Medicaid Services
RadioMedix Inc. and its commercial partner, Curium, announced today, December 9, 2020, that the Centers for Medicare & Medicaid Services (CMS) “has granted Detectnet Transitional Pass-Through Status (code C9068) effective January 1, 2021. The descriptor for Detectnet will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. C9068 will be used to bill Detectnet for Medicare patients seen in the hospital outpatient department.” An additional imaging option for the #NeuroendocrineTumor community! https://www.globenewswire.com/…/RadioMedix-Curium…
Next Generation Germanium-68/Gallium-68 Generator
ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies in Germany, and RadioMedix Inc., a clinical stage biotechnology company in Houston, Texas, announced on December 8, 2020, that the U.S. Food and Drug Administration (FDA) has issued the Drug Master File (DMF no. 34938) for ITM’s next generation Germanium-68/Gallium-68 (68Ge/68Ga) Generator, distributed under the brand name GeGant®.The DMF will enable companies interested in developing new drugs for the U.S. market to refer to the DMF and use GeGant® in clinical tests for radiopharmaceuticals and in other settings. This is especially significant for the #NeuroendocrineTumor community. Read more, https://www.streetinsider.com/…/FDA+has…/17693651.html
FDA Approves New NET Diagnostic Imaging Radiopharmaceutical
The U.S. Food and Drug Administration (FDA) has approved Detectnet™, copper Cu 64 dotatate injection. This is a new diagnostic radiopharmaceutical for use with positron emission tomography (PET) for the detection, localization, and monitoring of somatostatin receptor positive NETs. Read more about copper Cu 64, https://www.curiumpharma.com/2020/01/07/fda-new-drug-filing-cu-64/
NANETS 2020 Grant Recipients
Exciting news from NANETS, the North American Neuroendocrine Tumor Society, about the 2020 Research Grant Recipients. Congratulations to Dr. Heloisa Soares of the Huntsman Cancer Institute, University of Utah; Dr. Xavier Keutgen of the University of Chicago Medical Center; and Dr. Brendan Finnerty of Weill Cornell Medicine! Read more about the grants and the recipients here, https://nanets.net/research/grant-recipients.
Promising Developments in the Pipeline for High Grade Neuroendocrine Tumor Diagnosis and Treatment
“Treatment for high grade neuroendocrine neoplasms (abnormal tissue growth) is moving the way that the treatment for triple negative breast cancer is moving — toward the realization that there are a basket of subtypes and that each can be potentially treated differently,” according to Aman Chauhan, MD, medical oncologist, Director of NET Theranostics, Markey Cancer Center (NCI Designated Cancer Center), University of Kentucky. Insights gained through clinical trials will change how these cancers are diagnosed and treated. Read more
CCF Infographic: 6 Questions to Ask Your Doctor
Have you or someone you love been diagnosed with a neuroendocrine tumor or carcinoid cancer? It can feel like a daunting task to figure out next steps and doctor appointments may be overwhelming. You can help yourself or support a loved-one by learning about the disease and preparing yourself for doctor visits. The first visit may be the most challenging, so It’s important to arm yourself with relevant questions. Here we provide you with six questions, specific to neuroendocrine tumors, to ask your doctor. Click here to download the infographic.
Carcinoid Syndrome Website
The Carcinoid Cancer Foundation’s website www.carcinoidsyndrome.org is a space for everything about carcinoid syndrome – from diagnosis and treatment to news and community updates. This site is a great resource for patients, caregivers, and physicians alike – looking to learn more about carcinoid syndrome.
Guide to Understanding Carcinoid Syndrome
Know the signs and symptoms — skin flushing, diarrhea, heart racing . . . it could be carcinoid syndrome! How is it diagnosed, what are the treatment options, what questions should you ask your healthcare provider? Read more in Guide to Understanding Carcinoid Syndrome, from Health Monitor and the Carcinoid Cancer Foundation: https://www.carcinoid.org/wp-content/uploads/2015/10/Carcinoid-Syndrome-Guide-to-Understanding.pdf.
Reaching Those Who Are Still Undiagnosed
To combat statistics showing that it often takes 5 to 7 years for patients to receive the correct diagnosis of a neuroendocrine tumor (NET), the Carcinoid Cancer Foundation has partnered with Advanced Accelerator Applications to create an infographic listing common symptoms and misdiagnoses. Please share this broadly in hopes of helping others get the proper diagnosis more quickly. Download the infographic here.